Published:

Shire Ltd - Second Quarter 2008 Results Date Notification - 31 July 2008

BASINGSTOKE, England andPHILADELPHIA, July 4 /PRNewswire-FirstCall/ -- Shire Limited (LSE:SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, will announce second quarter 2008 earnings on Thursday 31 July 2008

    Results press release will be issued at:    12:00 BST / 07:00 EDT
    Investor meeting and conference call time:  14:30 BST / 09:30 EDT

Investor & Analyst meeting and conference call:

Angus Russell, Chief Executive Officer, Graham Hetherington, Chief Financial Officer, Mike Cola, President, Specialty Pharmaceuticals and Sylvie GrÃ©goire, President, Human Genetic Therapies will host the investor and analyst meeting and conference call at 14:30 BST/9:30 EDT.

The meeting will take place at Holborn Bars, 138-142 Holborn,London EC1 2NQ.

Please email claire.rowell@fd.com to register to attend this meeting in London.

    The details of the conference call are as follows:

    UK and International dial in      +44-(0)-203-023-4496
    US dial in:                       +1-866-966-5335
    Password/Conf ID:                 Shire

Live Webcast:

The call will also be available live over the Internet via audio webcast, accessible through www.shire.com in the investors section. A slide presentation to accompany the call will also be available on the Shire website.

Replay:

A replay of the presentation will be available for two weeks by phone and by webcast for one year. Details are as follows:

    UK and International dial in      +44-(0)-208-196-1998
    US dial in                        +1-866-583-1035
    Pin code                          3008632
    Webcast replay:                   http://www.shire.com, in the investors
                                      section


    Notes to Editors
    SHIRE LIMITED

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US orEurope. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

    For further information please contact:

    Investor Relations
    Souheil Salah (Rest of the World)    +44-1256-894-160
    Emily Berish (North America)         +1-484-595-8546

SOURCE Shire Ltd

Tags: ,BIO,HEA,MTC,ERN,CCA,Shire-Ltd

_ _

Is your favorite bookmark site missing? Ask for it.